Loading
Pancreatic Function and Diabetes / Diabetes, Cardiovascular Risks, and Lipoproteins · Journal article
Disease Models & Mechanisms · August 6, 2026
Early or partial results. Treat as a signal, not a conclusion.
This preclinical study demonstrates that fixed-dose (rather than weight-adjusted) streptozotocin combined with high-fat diet produces a more stable and reproducible type 2 diabetes-like phenotype in C57BL/6J mice, with lower inter-individual variability. A mathematical model supports the hypothesis that conventional weight-adjusted dosing introduces variability, particularly in diet-induced obese animals. The work is methodological and addresses reproducibility in rodent research; it does not inform clinical management.
Preclinical comparative experimental study with mathematical modelling. C57BL/6J mice receiving chow or high-fat diet. Intervention: Low-dose or high-dose fixed streptozotocin (anomer-equilibrated) combined with high-fat diet. Compared with: High-fat diet alone, chow diet, and conventional weight-adjusted streptozotocin dosing (in mathematical model predictions).
Low-dose fixed STZ with HFD induced stable T2D-like phenotype with sustained obesity, moderate hyperglycaemia, insulin resistance, and partial β-cell loss, with low inter-individual variability High-dose fixed STZ induced T1D-like phenotype with extensive β-cell loss Mathematical model predicted that weight-adjusted (mg/kg) dosing introduces variability in glycaemic responses, particularly in HFD-fed mice
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work is relevant to researchers designing rodent models of type 2 diabetes for mechanistic or therapeutic studies; it does not directly guide clinical practice. Adoption of fixed-dose rather than weight-adjusted streptozotocin may improve reproducibility and reduce study failure in preclinical metabolic research.
This is a methodological study in rodent disease models with mechanistic validation; it does not address human clinical outcomes and presents an improved technical approach rather than a practice-changing finding.
As stated by the source record.
Quoted from the source exactly as published.
This work is relevant to researchers designing rodent models of type 2 diabetes for mechanistic or therapeutic studies; it does not directly guide clinical practice. Adoption of fixed-dose rather than weight-adjusted streptozotocin may improve reproducibility and reduce study failure in preclinical metabolic research.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
High-fat diet (HFD) combined with streptozotocin (STZ) is widely used to model type 2 diabetes (T2D) in rodents, but is often associated with high mortality, non-responders, and inconsistent outcomes. STZ is conventionally administered using body weight-adjusted dosing (mg/kg), despite evidence that heavier animals, including HFD-fed mice, exhibit more severe glycaemic responses. Here, we performed metabolic phenotyping in chow- and HFD-fed C57BL/6J mice treated with low or high fixed doses (mg instead of mg/kg) of anomer-equilibrated STZ. HFD combined with low-dose STZ induced a stable T2D-like phenotype characterized by sustained obesity, moderate hyperglycaemia, insulin resistance, and partial β-cell loss, with low inter-individual variability. In contrast, high-dose STZ induced a T1D-like phenotype with extensive β-cell loss. A semi-mechanistic mathematical model was developed and validated against independent experimental data, reproducing the observed dynamics of fasting glucose in response to fixed-dose STZ. The model further predicted that weight-adjusted (mg/kg) dosing could introduce variability in glycaemic responses, particularly in HFD-fed mice. Together, these results demonstrate that fixed-dose, anomer-equilibrated STZ induces a stable T2D-like phenotype, providing an alternative to conventional weight-adjusted dosing in HFD-fed mice.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.